Jennifer Ann Johnson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penicillin G Benzathine | 1 | 2018 | 26 | 0.750 |
Why?
|
| AIDS Vaccines | 5 | 2018 | 887 | 0.700 |
Why?
|
| Syphilis | 1 | 2018 | 208 | 0.630 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2014 | 48 | 0.570 |
Why?
|
| Endocarditis, Bacterial | 2 | 2020 | 423 | 0.530 |
Why?
|
| Nasal Cavity | 1 | 2014 | 301 | 0.480 |
Why?
|
| Anti-Bacterial Agents | 7 | 2020 | 6829 | 0.480 |
Why?
|
| Encephalitis, Viral | 1 | 2012 | 55 | 0.470 |
Why?
|
| Endocarditis | 4 | 2020 | 319 | 0.470 |
Why?
|
| HIV-2 | 1 | 2012 | 155 | 0.460 |
Why?
|
| Actinomycetales Infections | 1 | 2011 | 34 | 0.440 |
Why?
|
| Actinomycetales | 1 | 2011 | 47 | 0.440 |
Why?
|
| Rheumatic Heart Disease | 1 | 2012 | 171 | 0.440 |
Why?
|
| Pleurisy | 1 | 2011 | 56 | 0.430 |
Why?
|
| Carrier State | 1 | 2014 | 544 | 0.420 |
Why?
|
| Bacteremia | 3 | 2020 | 945 | 0.410 |
Why?
|
| Drug Carriers | 3 | 2018 | 737 | 0.410 |
Why?
|
| HIV Infections | 9 | 2018 | 14979 | 0.390 |
Why?
|
| Foot Diseases | 1 | 2010 | 151 | 0.370 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 628 | 0.360 |
Why?
|
| Propionates | 1 | 2009 | 193 | 0.360 |
Why?
|
| Anti-HIV Agents | 3 | 2013 | 3955 | 0.350 |
Why?
|
| Acidosis | 1 | 2009 | 261 | 0.350 |
Why?
|
| Adenoviruses, Human | 3 | 2014 | 303 | 0.330 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 604 | 0.330 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2020 | 449 | 0.320 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 1917 | 0.290 |
Why?
|
| Genetic Vectors | 3 | 2018 | 3628 | 0.280 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 1513 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 6464 | 0.270 |
Why?
|
| Thromboembolism | 1 | 2010 | 988 | 0.250 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2021 | 3365 | 0.250 |
Why?
|
| Bone Diseases, Infectious | 1 | 2020 | 18 | 0.210 |
Why?
|
| Sternotomy | 1 | 2021 | 126 | 0.210 |
Why?
|
| HIV-1 | 6 | 2018 | 6711 | 0.210 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2021 | 140 | 0.200 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 1594 | 0.180 |
Why?
|
| Buprenorphine | 2 | 2020 | 489 | 0.170 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 1659 | 0.160 |
Why?
|
| Doxycycline | 1 | 2018 | 308 | 0.160 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 4132 | 0.160 |
Why?
|
| Contact Tracing | 1 | 2018 | 244 | 0.160 |
Why?
|
| Treatment Refusal | 1 | 2020 | 435 | 0.150 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 317 | 0.150 |
Why?
|
| Fatal Outcome | 3 | 2010 | 1939 | 0.150 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 1363 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 2 | 2010 | 5015 | 0.150 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 4064 | 0.140 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 6450 | 0.140 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2014 | 46 | 0.140 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 347 | 0.140 |
Why?
|
| Hospitals, Urban | 2 | 2014 | 502 | 0.140 |
Why?
|
| Canarypox virus | 1 | 2013 | 10 | 0.140 |
Why?
|
| Orthopoxvirus | 1 | 2013 | 10 | 0.140 |
Why?
|
| Neck | 1 | 2018 | 691 | 0.130 |
Why?
|
| Viridans Streptococci | 1 | 2012 | 18 | 0.130 |
Why?
|
| Toes | 2 | 2010 | 197 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2021 | 1464 | 0.120 |
Why?
|
| Minnesota | 1 | 2012 | 380 | 0.110 |
Why?
|
| Gene Products, env | 1 | 2012 | 261 | 0.110 |
Why?
|
| Brain Abscess | 1 | 2012 | 117 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 952 | 0.110 |
Why?
|
| Ritonavir | 1 | 2012 | 279 | 0.110 |
Why?
|
| Brain | 4 | 2012 | 24202 | 0.110 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2012 | 857 | 0.110 |
Why?
|
| Immunity, Mucosal | 1 | 2014 | 496 | 0.110 |
Why?
|
| Capsid Proteins | 1 | 2014 | 460 | 0.110 |
Why?
|
| DNA, Ribosomal | 1 | 2011 | 315 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 307 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 13603 | 0.100 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 335 | 0.100 |
Why?
|
| Infarction | 1 | 2010 | 191 | 0.090 |
Why?
|
| Methicillin Resistance | 2 | 2006 | 202 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 411 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2012 | 2578 | 0.090 |
Why?
|
| Viral Load | 3 | 2012 | 3216 | 0.090 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2021 | 2096 | 0.090 |
Why?
|
| Adenoviridae | 1 | 2013 | 1165 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2769 | 0.090 |
Why?
|
| Vaccines, Synthetic | 3 | 2018 | 540 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2020 | 2763 | 0.090 |
Why?
|
| Fontan Procedure | 1 | 2014 | 741 | 0.090 |
Why?
|
| Blood | 1 | 2011 | 628 | 0.090 |
Why?
|
| Staphylococcus aureus | 2 | 2006 | 1379 | 0.090 |
Why?
|
| Humans | 26 | 2021 | 686663 | 0.090 |
Why?
|
| Streptococcal Infections | 1 | 2012 | 643 | 0.090 |
Why?
|
| Oxacillin | 1 | 2006 | 35 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 1443 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2020 | 2754 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2012 | 889 | 0.080 |
Why?
|
| Thrombosis | 1 | 2020 | 2759 | 0.080 |
Why?
|
| Embolism | 1 | 2009 | 386 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2012 | 1899 | 0.080 |
Why?
|
| Adenine | 1 | 2012 | 894 | 0.080 |
Why?
|
| Fingers | 1 | 2010 | 512 | 0.080 |
Why?
|
| Medical Records | 1 | 2012 | 1425 | 0.080 |
Why?
|
| Male | 16 | 2020 | 352465 | 0.080 |
Why?
|
| Basal Ganglia | 1 | 2009 | 558 | 0.080 |
Why?
|
| Microscopy | 1 | 2011 | 853 | 0.080 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 1572 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 5182 | 0.070 |
Why?
|
| Middle Aged | 12 | 2020 | 216468 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1364 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2020 | 67320 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 1335 | 0.070 |
Why?
|
| RNA, Viral | 1 | 2012 | 2823 | 0.060 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 460 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2010 | 1109 | 0.060 |
Why?
|
| HIV Antibodies | 3 | 2014 | 1201 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 20409 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2010 | 978 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2014 | 1990 | 0.060 |
Why?
|
| Bone Wires | 1 | 2021 | 124 | 0.060 |
Why?
|
| Adult | 10 | 2020 | 211400 | 0.060 |
Why?
|
| Placebos | 2 | 2018 | 1791 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2021 | 60991 | 0.050 |
Why?
|
| Sternum | 1 | 2021 | 169 | 0.050 |
Why?
|
| Ischemia | 1 | 2010 | 1886 | 0.050 |
Why?
|
| Gene Expression | 1 | 2014 | 8182 | 0.050 |
Why?
|
| Echocardiography | 1 | 2012 | 5097 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 33186 | 0.050 |
Why?
|
| Bone Plates | 1 | 2021 | 418 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 5044 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 15075 | 0.050 |
Why?
|
| Weight Loss | 1 | 2010 | 2396 | 0.040 |
Why?
|
| Heart Failure | 1 | 2020 | 9179 | 0.040 |
Why?
|
| Vaccines, Subunit | 1 | 2018 | 137 | 0.040 |
Why?
|
| Female | 11 | 2020 | 375459 | 0.040 |
Why?
|
| Catheters | 1 | 2020 | 304 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15407 | 0.040 |
Why?
|
| Naltrexone | 1 | 2020 | 254 | 0.040 |
Why?
|
| Methadone | 1 | 2020 | 260 | 0.040 |
Why?
|
| Pulmonary Circulation | 1 | 2020 | 764 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2014 | 1626 | 0.040 |
Why?
|
| Young Adult | 5 | 2018 | 56052 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2014 | 38732 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 8070 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2018 | 11866 | 0.040 |
Why?
|
| Vaccinia virus | 1 | 2018 | 326 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 19328 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 894 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 4076 | 0.040 |
Why?
|
| Child | 3 | 2014 | 71361 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 534 | 0.040 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 3037 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2018 | 554 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2014 | 141 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 33918 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 16227 | 0.030 |
Why?
|
| Liver | 1 | 2010 | 7653 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2014 | 561 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 41159 | 0.030 |
Why?
|
| Propionibacterium acnes | 1 | 2012 | 75 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2021 | 1630 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2012 | 23953 | 0.030 |
Why?
|
| Risk Factors | 3 | 2021 | 69278 | 0.030 |
Why?
|
| Adolescent | 4 | 2014 | 84957 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 1880 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 1734 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 4807 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 174 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2014 | 49071 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 276 | 0.030 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 134 | 0.030 |
Why?
|
| HIV Antigens | 1 | 2010 | 354 | 0.020 |
Why?
|
| Cryoglobulinemia | 1 | 2009 | 84 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 9114 | 0.020 |
Why?
|
| Hemianopsia | 1 | 2009 | 122 | 0.020 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2009 | 181 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2009 | 340 | 0.020 |
Why?
|
| Hospitalization | 1 | 2006 | 9304 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2020 | 10108 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2020 | 2917 | 0.020 |
Why?
|
| Colon | 1 | 2014 | 1793 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2009 | 1700 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2006 | 289 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 1572 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 1717 | 0.020 |
Why?
|
| Shock | 1 | 2006 | 318 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 162271 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 2913 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 617 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 3116 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2010 | 4168 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 13444 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2006 | 1163 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 4355 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 6632 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 170849 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2010 | 5778 | 0.010 |
Why?
|
| Cytokines | 1 | 2014 | 7147 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 13606 | 0.010 |
Why?
|
| Alleles | 1 | 2010 | 7140 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 2892 | 0.010 |
Why?
|
| Cross Infection | 1 | 2006 | 1387 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 4115 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2009 | 6435 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13807 | 0.010 |
Why?
|
| African Americans | 1 | 2010 | 5144 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13204 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2006 | 5065 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 11019 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12734 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15296 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 19295 | 0.010 |
Why?
|
| Incidence | 1 | 2006 | 20496 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 42271 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 59331 | 0.000 |
Why?
|